MarginsXMarginsX
Home › Markets › Health Care › SDGR

Schrodinger Inc. (SDGR)

SDGR trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$27.36
-7.35% on the day
Market cap
$2.1B
Mid cap
Revenue · 2025
$255.9M
+23.3% on 2024
Net income · 2025
-$103.3M
-40.4% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1490978/000149097826000010/0001490978-26-000010-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerSDGR on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2020
SEC CIK0001490978
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2025

LineValue
Revenue$255.9M
Net income-$103.3M
Operating income-$166.9M
Net margin-40.4%
Operating margin-65.2%
Revenue growth+23.3%
Cash$230.5M
Total assets$726.2M
P/E (computed)Net income was not positive
P/S (computed)8.0×

Warning signs

Cash runway
26.3 months
$247.0M cash at September 30, 2026
Share count, 1 year
+1.9%
2025-10-31 to 2026-10-28
Going-concern doubt
No
10-Q filed November 4, 2026
Insider net buying, 12 months
-$2.3M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-04
Cash and burn$247.0M cash; operating cash flow -$28.1M a quarter.Report 2026-09-30
Shares outstanding75,077,794 (2026-10-28); 73,664,703 a year earlier.Cover page 2026-10-28
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorKPMG LLP, Portland, Oregon, United StatesPCAOB Form AP 2026-03-30
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $2.3M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$64.5M-$37.7M-$47.6M$247.0MNo debt tags$269.2M10-Q 2026-11-04
Q2 2026
2026-06-30
$58.9M$6.0M-$34.1M$287.9MNo debt tags$259.0M10-Q 2026-08-05
Q1 2026
2026-03-31
$58.6M-$60.0M-$14.8M$260.3MNo debt tags$254.9M10-Q 2026-05-05
Q4 2025
2025-12-31
$87.2M$32.5M-$16.1M$230.5MNo debt tags$255.9M10-K 2026-02-25
Q3 2025
2025-09-30
$54.3M-$32.8M-$61.9M$172.1MNo debt tags$257.0M10-Q 2026-11-04
Q2 2025
2025-06-30
$54.8M-$43.2M-$52.2M$219.9MNo debt tags$237.9M10-Q 2026-08-05
Q1 2025
2025-03-31
$59.6M-$59.8M$144.1M$326.0MNo debt tags$230.5M10-Q 2026-05-05
Q4 2024
2024-12-31
$88.3M-$40.2M-$31.1M$147.3MNo debt tags$207.5M10-K 2026-02-25

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering documentS-3ASR2024-02-28
Latest annual report10-K2026-02-25
Latest quarterly / interim10-Q2026-11-04
Latest current report8-K2026-11-04
Latest proxyDEFA14A2026-04-28

Source: SEC EDGAR submissions feed, 545 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-1.0%
1 month+14.1%
3 months+60.0%
Year to date+65.2%
1 year+71.7%
From 52-week high-11.6%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
AUPHAurinia Pharmaceuticals Inc$15.48-1.59%$2.1B
IMNMImmunome Inc.$17.61-6.18%$2.1B
BHVNBiohaven Ltd. Common Shares$13.80-0.14%$2.1B
PVLAPalvella Therapeutics Inc.$144.60-5.17%$2.1B
SEPNSepterna Inc.$41.67-2.18%$2.0B
TRAXFirst Tracks Biotherapeutics Inc. Ordinary Shares$46.56-1.15%$2.0B
VERAVera Therapeutics Inc.$26.97-4.02%$1.9B
HRMYHarmony Biosciences Holdings Inc.$32.96-2.37%$1.9B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier